Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date † | September 12, 2005 | ||||
Last Updated Date | November 6, 2008 | ||||
Start Date † | |||||
Current Primary Outcome Measures † |
Afebrile at 24 hours and no endometritis | ||||
Original Primary Outcome Measures † | Same as current | ||||
Change History | Complete list of historical versions of study NCT00185991 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures † |
Neonatal outcomes | ||||
Original Secondary Outcome Measures † | Same as current | ||||
Descriptive Information | |||||
Brief Title † | Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis | ||||
Official Title † | Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis | ||||
Brief Summary | To compare once daily versus 8 hour dosing of gentamicin for the treatment of chorioamnionitis. |
||||
Detailed Description | |||||
Study Phase | |||||
Study Type † | Interventional | ||||
Study Design † | Treatment, Randomized, Double-Blind, Active Control, Single Group Assignment, Efficacy Study | ||||
Condition † | Chorioamnionitis | ||||
Intervention † | Drug: gentamicin | ||||
Study Arms / Comparison Groups | |||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status † | Active, not recruiting | ||||
Enrollment † | 0 | ||||
Completion Date | |||||
Primary Completion Date | |||||
Eligibility Criteria † | Inclusion Criteria::
|
||||
Gender | Female | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts †† | |||||
Location Countries † | United States | ||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID † | NCT00185991 | ||||
Responsible Party | |||||
Secondary IDs †† | |||||
Study Sponsor † | Stanford University | ||||
Collaborators †† | |||||
Investigators † |
|
||||
Information Provided By | Stanford University | ||||
Verification Date | November 2008 | ||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |